Gubra

Based in Denmark, Gubra is a non-clinical CRO with strengths in metabolic diseases and fibrosis. It provides rapid and reliable drug discovery support by utilizing its proprietary pathological models and advanced analytical technologies. Here, we introduce in detail the features of Gubra's services and specific study cases.

Features of Gubra's Contract Non-clinical Trial Services

Specialization and reliability in the area of metabolism and fibrosis

Gubra is deeply specialized in the metabolic and fibrosis areas of obesity, diabetes, and MASH (metabolic insufficiency related steatohepatitis). The company's major strength is that it is an "R&D-oriented" company with its own drug discovery pipeline, not merely a contract research company.

Our scientific proposals are very practical, based on abundant research data and experience gained from our actual in-house drug discovery activities. We believe that we can be your reliable partner to lead your drug discovery project to success.

Advanced technology using AI analysis and 3D imaging

Another major advantage of selecting Gubra is its proactive implementation of advanced technologies to improve data quality. In particular, 3D imaging technology, which makes entire organs transparent for imaging, and AI-based histological analysis provide extremely accurate data.

It visualizes microscopic lesions and drug distribution that cannot be captured by conventional analysis methods and can be used as objective evidence. It is a powerful weapon for researchers who want to make more reliable decisions.

An example of Gubra's pathological model

MASH (steatohepatitis) model that faithfully reproduces human pathology

Gubra's GAN DIO-MASH mouse model faithfully reflects human pathophysiology. It is highly valued for its ability to confirm progression by liver biopsy and provide highly predictive clinical data.

This is a strong option for those looking for a highly accurate test system.

Obesity and diabetes models with extensive experience

The high-fat diet-induced obesity (DIO) model, with over 15 years of experience, is another of Gubra's major strengths. In addition to food intake and energy metabolism, Gubra supports a wide range of assessments, including brain activation signatures.

The model, filled with our unique know-how, will greatly contribute to the elucidation of the mechanism of action.

Gubra Non-clinical Case Studies

Imaging case study to visualize drug action in the brain in 3D

Gubra's "Whole Brain 3D Imaging" is a revolutionary technology that visualizes which parts of the brain are activated by a drug. For example, in the evaluation of anti-obesity drugs, Gubra has successfully mapped the expression of "c-Fos," an indicator of neural activity, at the single cell level to identify the mechanism of action (MoA) of the drug.

A major advantage of this method is that the entire brain is analyzed without slicing, so the entire picture can be obtained without omission. This can be used as a convincing scientific basis for the development of drugs that act on the central nervous system.

Application of AI Pathology Analysis in Renal Disease Models

Image analysis using artificial intelligence (AI) has been successful in tests to evaluate fibrosis in kidneys. Using AI, the quantification of fibrosis areas, which tends to vary with conventional visual evaluation by pathologists, can be done quickly and objectively.

There have been cases where the effect of microscopic treatment was accurately detected in models of chronic kidney disease (CKD) and diabetic kidney disease (DKD). This is a reliable analysis method for researchers who value data reproducibility.

Gubra Company Information

Headquartered in Denmark, Gubra is a highly specialized biotechnology company focused on the metabolic and fibrosis areas. The company accelerates drug development worldwide through both advanced contract non-clinical research services (CRO) and in-house peptide drug discovery research.